**Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy** This study is testing a new medicine called RPT904. It's for people who have food allergies caused by something called IgE, which is a part of the immune system that reacts to certain foods. RPT904 is a special kind of medicine known as a monoclonal antibody, which is like a tiny helper that can stop IgE from causing allergies. The study will see if RPT904 helps people eat more of a food they're allergic to without getting sick. People in the study will be between 12 and 55 years old and allergic to foods like peanuts, milk, eggs, cashews, or walnuts. The study lasts about 68 to 74 weeks and is conducted at several locations. Participants will have to visit the study site every 2 to 6 weeks. **Key Points:** - Study duration is 68-74 weeks with frequent visits. - Participants will receive RPT904 or placebo, later re-randomized if on placebo. - The study aims to see if RPT904 increases food tolerance and monitor safety.